UnitedHealth Group Inc. (UNH)

UnitedHealth Group's stock sits 12.71% below its 52-week high of $461.62 after a flat stretch, yet it remains above its 50-day and 200-day moving averages ($391.19 and $365.31). The most recent earnings report, dated October 13, 2026, beat the analysts' EPS estimate by 13.29%, but the share price slipped 0.20% in the first session after it. CleaRank rates the stock Buy with a score of 75/100, the same rating as the analysts' Buy consensus.

UnitedHealth reported adjusted EPS of $4.69 for the report dated October 13, 2026, against an analysts' estimate of $4.14, a beat of 13.29%. That was the second straight beat, after $6.38 against $4.92 in July and $7.23 against $6.60 in April, though the stock rose 6.96% after the April report and only 0.20% after the October one. Profit is therefore rising faster than sales, which is the opposite of what investors often want to see in a large healthcare company. The margins show how thin that profit still is. The net profit margin is 3.53% and the operating margin is 5.82%, yet return on equity is 15.77%, well above the sector median of 7.3%. Debt-to-equity of 0.70 gives the balance sheet room. For an investor, the question is whether the earnings beats come from cost control that can last, and whether revenue turns positive again to support them.

The stock trades at a trailing P/E of 23.00, a discount to peers, against a sector median of 31.9. Its price-to-sales ratio of 0.81 is far below the sector median of 3.4. The market is paying less for each dollar of earnings and each dollar of sales than for most healthcare companies, which is the main reason the valuation factor scores strongly for CleaRank. Insider activity over the last 18 months leans toward buying. Insiders made open-market purchases worth $31.6M across five transactions, against $1.1M of sales across five transactions. Insider sales are often planned in advance or made to cover tax on vesting shares, so the purchases carry more weight as a signal.

Analysts remain constructive. Of 26 analysts with a current rating, 21 rate the stock buy or strong buy, 5 hold and none sell. Three months ago 23 of 27 ratings were buy, so the group has not shifted against the stock. On October 27, 2026, Wells Fargo and Morgan Stanley both kept their Overweight ratings, and Mizuho, RBC Capital, Bernstein and JP Morgan kept their ratings between October 16 and October 22. The trend is clearly up. The price is 3.00% above its 50-day SMA and 10.30% above its 200-day SMA, and the 50-day average is 7.09% above the 200-day average. Over one year the stock is up 23.05%, although it has returned only 0.44% over six months and 0.65% over three months, so the gains have come in stages. The 14-day RSI of 52.2 is in the neutral zone, and the MACD line is positive.

The base case is that the stock holds above its moving averages while earnings keep beating estimates, with the price trading in a range set by the 20-day EMA below and the 52-week high above. Analysts' expected EPS growth of 25.9% this fiscal year and 13.1% next year is the core of the bull argument, and the median 12-month target of $490.00 sits 21.6% above the price. Revenue is the weak point: analysts expect revenue to grow only 0.3% this fiscal year, so a return to top-line growth would support the premium the market is paying for earnings. The lowest analyst target of $380.00 sits above that average. Simulations from past volatility are not forecasts, and the stock's typical daily move of 1.73% means large swings remain normal.

Nearest support is the 20-day EMA at $401.48, a level the price sits just above. Below it, the 50-day SMA at $391.19 is the next floor the stock would meet on a fall, and it has been a reference point for the uptrend. The 200-day SMA at $365.31 is the deeper support, the average that marks the long-term trend. Resistance is the 52-week high at $461.62, the first level a rally would meet, and a close above it would mark a new high for the year.